Intravenous immunoglobulin therapy for diabetic amyotrophy

Internal Medicine

Volumn 40, Issue 4, 2001, Pages 349-352

  Ogawa, Tomoko ^a   Taguchi, Tomohiro ^a   Tanaka, Yasuhumi ^a   Ikeguchi, Kunihiko ^a   Nakano, Imaharu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Bruns Garland syndrome; Diabetic proximal neuropathy; Immunomodulating agent; Inflammatory neuropathy

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG EFFECT; ELECTROPHYSIOLOGY; FEMALE; HUMAN; MUSCLE ATROPHY; MUSCLE WEAKNESS;

EID: 0035019625     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.40.349     Document Type: Article

References (17)

1. O'Hare JA, Abuaisha F, Geoghegan M. Prevalence and forms of neuropathic morbidity in 800 diabetics. Ir J Med Sci 163: 132-135, 1994.
2. Sander HW, Chokroverty S. Diabetic amyotrophy : current concepts. Semin Neurol 16: 173-178, 1996.
3. Barohn RJ, Sahenk Z, Warmolts JR, Mendell JR. The Bruns-Garland syndrome (diabetic amyotrophy), revisited 100 years later. Arch Neurol 48: 1130-1135, 1991.
4. Llewelyn JG, Thomas PK, King RHM. Epineurial microvasculitis in proximal diabetic neuropathy. J Neurol 245: 159-165, 1998.
5. Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 35: 559-569, 1994.
6. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 52: 1053-1061, 1995.
7. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 316: 599-606, 1987.
8. Johnson PC, Doll SC, Cromey DW. Pathogenesis of diabetic neuropathy. Ann Neurol 19: 450-457, 1986.
9. Casey EB, Harrison MJG. Diabetic amyotrophy: a follow-up study. Br Med J 1: 656-659, 1972.
10. Coppack SW, Watkins PJ. The natural history of diabetic femoral neuropathy. Q J Med 79: 307-313, 1991.
11. Younger DS, Rosoklija G, Hays AP, Trojaborg W, Latov N. Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve 19: 722-727, 1996.
12. Dalakas MC. Intravenous immunoglobulin therapy for neurologic diseases. Ann Intern Med 126: 721-730, 1997.
13. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51: S2-8, 1998.
14. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 326: 107-116, 1992.
15. Ellie E, Combe C, Ferrer X. High-dose intravenous immune globulin and acute renal failure. N Engl J Med 327: 1032-1033, 1992.
16. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 44: 1180-1181, 1994.
17. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 2: 217-218, 1986.